CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Peg-Interferon alpha-2b +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00846430
NCT00846430Phase 2Completed
CompareCT.gov

Medical Treatment of "High-Risk" Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies

Corewell Health West·interventional·Posted Feb 18, 2009·Updated Aug 30, 2023

In Brief

A Phase 2 clinical trial evaluating Peg-Interferon alpha-2b, Celecoxib (Celebrex), and 2 other interventions for Neurofibromatosis 1. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medical therapy to offer patients with "high-risk" plexiform neurofibromas, and surgery does not provide lasting help. This study will evaluate the effectiveness of two treatment combinations in patients with "high-risk" plexiform neurofibromas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis 1
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2009
Enrollment StartOct 1, 2008
Primary CompletionApr 1, 2017
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 17.4 years ago

Interventions

Peg-Interferon alpha-2bdrug

age and weight dependant

Celecoxib (Celebrex)drug

age and weight dependant

Temozolomide (temodar)drug

age and weight dependant

Vincristine Sulfate (Oncovin)drug

age and weight dependant